Needham & Company analyst Alan Carr reiterates Buy and $62 price target on Neurocrine Biosciences (NASDAQ: NBIX), as the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View FDA

Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey DataFebruary 16, 2017 7:47 AM Baird Reiterates Outperform Rating and $66 PT on Neurocrine Biosciences (NBIX) Following 4Q ResultsFebruary 15, 2017 5:56 AM Neurocrine Bio. (NBIX) PT Raised to $60 at OppenheimerFebruary 15, 2017 12:50 AM Neurocrine Biosciences (NBIX) Tops Q4 EPS by 5cFebruary 14, 2017 4:11 PM Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017February 14, 2017 4:01 PM